Michael Aaron Morse
Professor of MedicineOverview
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.
Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.
Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma
Positions
Professor of Medicine in the School of Medicine
2012 School of Medicine
Professor in the Department of Surgery in the School of Medicine
2015 School of Medicine
Member of the Duke Cancer Institute in the School of Medicine
1993 School of Medicine
Education
M.D. 1990
1990 Yale University
Medical Resident, Medicine
1993 University of Washington
Fellow in Hematology-Oncology, Medicine
1996 Duke University
Publications, Grants & Awards
DCI Centers, Cancer Types & Labs
Offices & Contact
Durham, NC
27710 Duke Box 3233
Durham, NC
27710